| Delcath Systems, Inc. currently developing the Delcath Percutaneous Hepatic Perfusion System, or PHP, a minimally invasive drug delivery platform for the regional treatment of cancer metastatic to the liver, reported on the Company's recent progress. Eamonn P. Hobbs, President & CEO commented: "With the enrollment in our Phase III clinical study completed, we are now beginning to prepare our application to the FDA for marketing approval." "We continue to expect that we will submit the application to the FDA by the end of 1H of 2010. Meanwhile, we are optimistic about our ability to gain CE mark approval in Europe in early 2010 and expect to begin commercial sales in the European markets shortly thereafter. With the proceeds from the offering boosting our cash balance to more than $37M, and the potential opportunity to gain additional resources through international partnerships, we are very well positioned to execute on our strategies, expand the potential benefits of the PHP System to patients globally and build increasing returns to our shareholders." :theflyonthewall.com |
Subscribe for More Information